April 07, 2026

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant

March 26, 2026

FDA Clears AI Guidance Tool for Mitral Repair

AI enhances real-time intraprocedural visualization and navigation.

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 13, 2026

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Conexiant

February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant